ISPIRE Reports Strong Growth in Q2 FY2024: Operating Expenses Surge to $10.3 Million, Net Loss at $4 Million
According to the Nasdaq website on February 20th, the Nasdaq-listed company ISPIRE (NASDAQ: ISPR) announced its second quarter financial performance ending on December 31, 2023, and submitted its quarterly report on Form 10-Q on February 20, 2024.
In the second quarter of the 2024 fiscal year, the company's revenue increased by 30.7% compared to the same period in 2023, reaching $41.7 million. Specifically, revenue from tobacco vaporization products was $22.1 million, and revenue from cannabis vaporization products was $19.5 million.
Gross profit also increased by 24.1% from $5.1 million in the same period in 2023 to $6.4 million. The gross profit margin decreased from 16.1% in the same period in 2023 to 15.3%.
However, total operating expenses increased by 114% from $4.8 million in the same period in 2023 to $10.3 million, resulting in a net loss of $4 million compared to a net loss of $100,000 in the same period in 2023.
Michael Wang, CEO of ISPIRE, commented that this quarter is crucial for product expansion and business operations. The company has undertaken several strategic initiatives, including obtaining ISO and GMP certifications for their Malaysian factory, and obtaining Pre-Market Tobacco Product Application (PMTA) approval in the United States. With a significant growth trend in sales related to their cannabis vaporizer hardware, they aim to further strengthen their presence in this market and expand their business scope.
Chief Financial Officer Daniel Machock added that in the second quarter of 2024, key growth indicators for Ispire highlighted the rapid expansion of the cannabis e-cigarette hardware business, with overall revenue increasing by 30% to $41.7 million, while cannabis e-cigarette hardware product sales grew by 149% year-on-year to $19.5 million.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
